⚠ AI-Generated

The summary below was generated by an AI language model and may contain errors or omissions. All other content on this page is deterministically extracted from the original SEC EDGAR filing.

McKesson's 2025 10-K reflects a shift in risk emphasis, with the removal of foreign currency exposure and the addition of healthcare reform risks including pricing and reimbursement model changes. The majority of risk factor changes were substantive modifications rather than wholesale additions, with 17 risks substantially revised - notably including heightened disclosure around cybersecurity incidents, generic pharmaceutical distribution impacts, and strategic growth execution challenges. This restructuring suggests McKesson is recalibrating its risk narrative to prioritize regulatory and operational threats over currency volatility.

Classification is based on semantic text similarity scoring and may include approximations. “No match” means no high-confidence textual match was found — not necessarily that a section was removed.

🟢 New in Current Filing McKESSON CORPORATION 🔒

🟢 New in Current Filing We might be adversely impacted by healthcare reform such as changes in pricing and reimbursement models. 🔒

🟢 New in Current Filing McKESSON CORPORATION 🔒

🔴 No Match in Current Filing We might be adversely impacted by fluctuations in foreign currency exchange rates. 🔒

🔴 No Match in Current Filing McKESSON CORPORATION 🔒

🟡 Modified We experience cybersecurity incidents that might significantly compromise our technology systems or might result in material data breaches. 🔒

🟡 Modified INDEX TO RISK FACTORS 🔒

🟡 Modified We may be unsuccessful in achieving our strategic growth objectives. 🔒

🟡 Modified We are adversely impacted as a result of our distribution of generic pharmaceuticals. 🔒

🟡 Modified From time to time we are adversely impacted by delays or other difficulties with divestitures. 🔒

🟡 Modified Our contracts with governmental entities involve future funding and compliance risks. 🔒

🟡 Modified Pharmaceutical and medical products that we distribute might not conform to specifications or perform as intended. 🔒

🟡 Modified We might be unable to successfully recruit and retain qualified employees. 🔒

🟡 Modified McKESSON CORPORATION 🔒

🟡 Modified We might be unable to successfully complete or integrate acquisitions or other strategic transactions. 🔒

🟡 Modified Privacy, cybersecurity, data protection, and AI laws increase our compliance burden. 🔒

🟡 Modified We might lose our ability to purchase, store, or distribute pharmaceuticals, including controlled substances, and medical products. 🔒

🟡 Modified We are adversely impacted by changes in the economic environments in which we operate, including from inflation, an economic slowdown, a recession, or fluctuations in foreign currency exchange rates. 🔒

🟡 Modified We experience significant problems with information systems or networks. 🔒

🟡 Modified Conditions and events outside of our control, such as widespread public health issues, natural disasters, and geopolitical factors adversely impact our business operations and our financial position or results of operations. 🔒

🟡 Modified Evolving expectations and regulatory requirements related to governance and sustainability matters may damage our reputation and have an adverse effect on our business, financial condition, and results of operations. 🔒

🟡 Modified From time to time we have difficulties in sourcing or selling products due to a variety of causes and are adversely impacted by disruptions or changes in product supply. 🔒

23 changes in this historical filing

Historical year-over-year comparisons (2025 vs 2024 and earlier) are available on the Pro plan.

Get full access — from $29/month Already a Pro subscriber? View full diff →